NASDAQ:TELA - Nasdaq - US8723811084 - Common Stock - Currency: USD
NASDAQ:TELA (4/30/2025, 8:00:01 PM)
0.97
+0.03 (+3.18%)
The current stock price of TELA is 0.97 USD. In the past month the price decreased by -23.62%. In the past year, price decreased by -79.45%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ALC | ALCON INC | 32 | 48.78B | ||
COO | COOPER COS INC/THE | 21.66 | 16.33B | ||
ALGN | ALIGN TECHNOLOGY INC | 18.55 | 12.69B | ||
SOLV | SOLVENTUM CORP | 9.88 | 11.44B | ||
LNTH | LANTHEUS HOLDINGS INC | 15.39 | 7.15B | ||
MMSI | MERIT MEDICAL SYSTEMS INC | 26.46 | 5.58B | ||
BLCO | BAUSCH + LOMB CORP | 18.65 | 4.08B | ||
ICUI | ICU MEDICAL INC | 21.96 | 3.36B | ||
HAE | HAEMONETICS CORP/MASS | 14.9 | 3.17B | ||
XRAY | DENTSPLY SIRONA INC | 8.32 | 2.77B | ||
UFPT | UFP TECHNOLOGIES INC | 27.44 | 1.60B | ||
NEOG | NEOGEN CORP | 13.29 | 1.10B |
TELA Bio, Inc. is a commercial stage medical technology company, which focuses on the design, development, and market of tissue reinforcement materials. The company is headquartered in Malvern, Pennsylvania and currently employs 209 full-time employees. The company went IPO on 2019-11-08. The firm is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The firm's OviTex products include OviTex 1S, OviTex 2S, OviTex LPR, and OviTex IHR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.
TELA BIO INC
1 Great Valley Parkway, Suite 24
Malvern PENNSYLVANIA 19355 US
CEO: Antony Koblish
Employees: 227
Company Website: https://www.telabio.com/
Investor Relations: http://ir.telabio.com
Phone: 14843202930
The current stock price of TELA is 0.97 USD. The price increased by 3.18% in the last trading session.
The exchange symbol of TELA BIO INC is TELA and it is listed on the Nasdaq exchange.
TELA stock is listed on the Nasdaq exchange.
11 analysts have analysed TELA and the average price target is 5.92 USD. This implies a price increase of 509.9% is expected in the next year compared to the current price of 0.97. Check the TELA BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
TELA BIO INC (TELA) has a market capitalization of 38.36M USD. This makes TELA a Nano Cap stock.
TELA BIO INC (TELA) currently has 227 employees.
TELA BIO INC (TELA) has a resistance level at 0.98. Check the full technical report for a detailed analysis of TELA support and resistance levels.
The Revenue of TELA BIO INC (TELA) is expected to grow by 14.48% in the next year. Check the estimates tab for more information on the TELA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
TELA does not pay a dividend.
TELA BIO INC (TELA) will report earnings on 2025-05-08, after the market close.
TELA BIO INC (TELA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.39).
The outstanding short interest for TELA BIO INC (TELA) is 1.73% of its float. Check the ownership tab for more information on the TELA short interest.
ChartMill assigns a fundamental rating of 3 / 10 to TELA. TELA may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months TELA reported a non-GAAP Earnings per Share(EPS) of -1.39. The EPS increased by 32.85% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -43.71% | ||
ROE | -132.97% | ||
Debt/Equity | 1.45 |
ChartMill assigns a Buy % Consensus number of 82% to TELA. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 52.08% and a revenue growth 14.48% for TELA